Matthew W Foehr
CIK 1237556 · President and CEO · last filed 2026-04-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
LGND price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
LA JOLLA, CA 92037
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OABIW | President and CEO | 4,420,492 | $0.39 | $1.71M | $7.27M | 33 | 2026-04-07 |
| VKTX | Director | 135,186 | $24.22 | $3.27M | -$286.7K | 11 | 2026-01-05 |
| LGND | President and COO | 162,187 | $308.45 | $50.03M | -$31.25M | 58 | 2022-11-03 |
| Viking Therapeutics, Inc. (VKTXW) Delisted | Director | 46,250 | $4.60 | $212.7K | -$79.9K | 8 | 2021-03-25 |
| Qualigen Therapeutics, Inc. (RTTR) Delisted | Director | 5,545 | — | — | $133.1K | 12 | 2020-04-23 |
| Viking Therapeutics, Inc. (VKTX.W) Delisted | Director | 26,250 | — | — | $24.8K | 1 | 2016-04-13 |
Recent Filings · Page 3 of 14
134 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-11-26 | OABIW | Exer (M) | +99,434 | $370.7K | EDGAR |
| 2024-06-27 | OABIW | Exer (M) | +59,659 | $222.4K | EDGAR |
| 2024-05-28 | OABIW | Buy (P) | +240,000 | $1.06M | EDGAR |
| 2024-04-23 | OABIW | Grant (A) | +1,431,618 | $0 | EDGAR |
| 2024-04-09 | OABIW | Mixed | +17,981 | -$98.1K | EDGAR |
| 2024-03-29 | OABIW | Exer (M) | +243,613 | $907.0K | EDGAR |
| 2024-03-25 | OABIW | Buy (P) | +225,000 | $1.17M | EDGAR |
| 2024-02-20 | OABIW | Mixed | +18,409 | -$104.8K | EDGAR |
| 2024-01-04 | VKTX | Grant (A) | — | $0 | EDGAR |
| 2024-01-03 | OABIW | Mixed | +19,952 | -$82.6K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.